Theriva Biologics 過去の業績

過去基準チェック /06

Theriva Biologicsの収益は年平均-0.3%で減少しているが、Biotechs業界はgrowingで7.7%年平均の収益となった。

主要情報

-0.3%

収益成長率

60.6%

EPS成長率

Biotechs 業界の成長	-14.6%
収益成長率	n/a
株主資本利益率	-80.5%
ネット・マージン	n/a
前回の決算情報	30 Jun 2024

Recent updates

収支内訳

Theriva Biologics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:SFY0 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Jun 24	-22	7	15
31 Mar 24	-19	8	15
31 Dec 23	-18	8	14
30 Sep 23	-19	8	13
30 Jun 23	-21	9	12
31 Mar 23	-20	8	12
31 Dec 22	-20	8	12
30 Sep 22	-19	8	11
30 Jun 22	-17	7	11
31 Mar 22	-16	7	9
31 Dec 21	-23	6	8
30 Sep 21	-21	5	6
30 Jun 21	-20	5	5
31 Mar 21	-21	5	5
31 Dec 20	-13	5	5
30 Sep 20	-13	5	6
30 Jun 20	-15	5	9
31 Mar 20	-16	5	10
31 Dec 19	-16	5	11
30 Sep 19	-28	4	11
30 Jun 19	-26	5	10
31 Mar 19	-27	5	11
31 Dec 18	-25	6	12
30 Sep 18	-8	7	13
30 Jun 18	-22	7	15
31 Mar 18	-22	7	16
31 Dec 17	-22	8	19
30 Sep 17	-27	9	22
30 Jun 17	-18	9	25
31 Mar 17	-19	10	27
31 Dec 16	-27	10	29
30 Sep 16	-36	9	31
30 Jun 16	-34	9	34
31 Mar 16	-42	9	35
31 Dec 15	-44	8	33
30 Sep 15	-39	7	29
30 Jun 15	-37	7	23
31 Mar 15	-28	7	18
31 Dec 14	-20	6	14
30 Sep 14	-18	5	12
30 Jun 14	-16	6	10
31 Mar 14	-14	5	8

質の高い収益: SFY0は現在利益が出ていません。

利益率の向上: SFY0は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SFY0は利益が出ておらず、過去 5 年間で損失は年間0.3%の割合で増加しています。

成長の加速: SFY0の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SFY0は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -21.2% ) と比較することは困難です。

株主資本利益率

高いROE: SFY0は現在利益が出ていないため、自己資本利益率 ( -80.54% ) はマイナスです。

Theriva Biologics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Recent updates

Theriva Biologics, Inc. Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Theriva Biologics, Inc. has filed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

New major risk - Financial position

Theriva Biologics, Inc. Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation

Theriva Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $1.235303 million.

Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

New minor risk - Shareholder dilution

New major risk - Market cap size

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

High number of new and inexperienced directors

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004

Theriva Biologics, Inc. Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.

Synthetic Biologics, Inc. Notifies Clearance of Safety Evaluation Period

High number of new and inexperienced directors

Synthetic Biologics, Inc. Reports Positive Safety Data on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Synthetic Biologics, Inc. Announces Peer-Reviewed Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients with Advanced Solid Tumors

Synthetic Biologics, Inc. (NYSEAM:SYN) signed a definitive agreement to acquire VCN Biosciences SL from Grifols Innovation and New Technologies Limited and others for $85.6 million.

Synthetic Biologics Provides Update on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

Synthetic Biologics, Inc. Announces Clinical Development and Operational Update

Insider recently bought €144k worth of stock

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

New 90-day high: €1.23

Synthetic Biologics, Inc. Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Synthetic Biologics, Inc. Announces Executive Changes

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: €0.23

New 90-day low: €0.24

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2B Clinical Study of SYN-010 in IBS-C Patients

New 90-day low: €0.37

New 90-day high - €0.59

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06